Emergent BioSolutions, Inc., CEO named to U.S. Chamber of Commerce board of directors

Fuad El-Hibri, the chairman and CEO of Emergent BioSolutions, Inc., was recently appointed to the board of directors of the U.S. Chamber of Commerce.

EL-Hibri has been in charge at Emergent BioSolution, Inc., the maker of the only U.S. Food and Drug Administration approved anthrax vaccine, since 1998.  Before heading the company, El-Hibri worked in telecommunications, banking and consulting, according to BizJournals.com.

"Throughout his career, Fuad El-Hibri has successfully identified and expanded on business opportunities that contribute to creating jobs and growing the economy," U.S. Chamber CEO Thomas Donohue said, BizJournals.com reports. "The Chamber will benefit from his vast experience in international business and partnering with the U.S. government."

The U.S. Chamber of Commerce is considered to be one of the world’s largest business advocacy groups. It represents more than three million businesses, industry associations and state and local chambers.

Emergent BioSolutions, Inc., recently announced that it had entered talks with the U.S. government to provide an additional 44.75 million doses of BioThrax to the U.S. Strategic National Stockpile. The order would be more than twice the number of doses the company has been previously contracted to provide.

The company also recently completed a successful Phase I study that demonstrated the safety and immunogenicity of an adjuvanated version of BioThrax, dubbed NuThrax. The FDA granted NuThrax Fast Track regulatory status earlier this month.